XANDERLA implantaat süstlis Eesti - eesti - Ravimiamet

xanderla implantaat süstlis

teva b.v. - gosereliin - implantaat süstlis - 10,8mg 3tk; 10,8mg 2tk

RESELIGO implantaat süstlis Eesti - eesti - Ravimiamet

reseligo implantaat süstlis

zentiva k.s. - gosereliin - implantaat süstlis - 10,8mg 1tk; 10,8mg 3tk

ZOLADEX implantaat Eesti - eesti - Ravimiamet

zoladex implantaat

astrazeneca ab - gosereliin - implantaat - 3,6mg 1tk

XANDERLA implantaat süstlis Eesti - eesti - Ravimiamet

xanderla implantaat süstlis

teva b.v. - gosereliin - implantaat süstlis - 3,6mg 2tk; 3,6mg 3tk

NEXPLANON implantaat Eesti - eesti - Ravimiamet

nexplanon implantaat

organon n.v. - etonogestreel - implantaat - 68mg 5tk; 68mg 1tk

RESELIGO implantaat süstlis Eesti - eesti - Ravimiamet

reseligo implantaat süstlis

zentiva k.s. - gosereliin - implantaat süstlis - 3,6mg 3tk

DISULFIRAME implantaat Eesti - eesti - Ravimiamet

disulfirame implantaat

steruli - disulfiraam - implantaat - 100mg 12tk

Esperal impl.tabl. 100mg N10 implantaat Eesti - eesti - Ravimiamet

esperal impl.tabl. 100mg n10 implantaat

sanofi winthrop - disulfiraam - implantaat - 100mg 10tk

DISULFIRAM implantaat Eesti - eesti - Ravimiamet

disulfiram implantaat

warsaw pharmaceutical works polfa s.a. - disulfiraam - implantaat - 100mg 10tk

Zolsketil pegylated liposomal Euroopa Liit - eesti - EMA (European Medicines Agency)

zolsketil pegylated liposomal

accord healthcare s.l.u. - doxorubicin hydrochloride, liposomal - ovarian neoplasms; sarcoma, kaposi; multiple myeloma - doxorubicin - zolsketil pegylated liposomal is a medicine used to treat the following types of cancer in adults:• breast cancer that has spread to other parts of the body in patients at risk of heart problems. zolsketil pegylated liposomal is used on its own for this disease;• advanced ovarian cancer in women whose previous treatment including a platinum-based cancer medicine has stopped working;• multiple myeloma (a cancer of the white blood cells in the bone marrow), in patients with progressive disease who have received at least one other treatment in the past and have already had, or are unsuitable for, a bone marrow transplantation. zolsketil pegylated liposomal is used in combination with bortezomib (another cancer medicine);• kaposi’s sarcoma in patients with aids who have a very damaged immune system. kaposi’s sarcoma is a cancer that causes abnormal tissue to grow under the skin, on moist body surfaces or on internal organs. zolsketil pegylated liposomal contains the active substance doxorubicin and is a ‘hybrid medicine’. this means that it is similar to a ‘reference medicine’ containing the same active substance called adriamycin. however, in zolsketil pegylated liposomal the active substance is enclosed in tiny fatty spheres called liposomes, whereas this is not the case for adriamycin.